Castellan Group Grows Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Castellan Group raised its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 2.3% during the 4th quarter, Holdings Channel reports. The fund owned 116,470 shares of the biopharmaceutical company’s stock after purchasing an additional 2,672 shares during the period. Halozyme Therapeutics makes up approximately 2.4% of Castellan Group’s investment portfolio, making the stock its 17th biggest position. Castellan Group’s holdings in Halozyme Therapeutics were worth $5,568,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Heck Capital Advisors LLC purchased a new position in Halozyme Therapeutics in the fourth quarter worth about $29,000. GAMMA Investing LLC boosted its holdings in shares of Halozyme Therapeutics by 67.7% in the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 350 shares during the period. Toth Financial Advisory Corp purchased a new position in shares of Halozyme Therapeutics in the 3rd quarter worth approximately $57,000. FSC Wealth Advisors LLC bought a new position in shares of Halozyme Therapeutics during the 3rd quarter valued at approximately $65,000. Finally, CWM LLC raised its holdings in Halozyme Therapeutics by 77.5% during the 3rd quarter. CWM LLC now owns 1,530 shares of the biopharmaceutical company’s stock valued at $88,000 after buying an additional 668 shares during the period. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Trading Up 1.4 %

Shares of Halozyme Therapeutics stock opened at $58.11 on Thursday. The firm’s 50 day simple moving average is $52.09 and its two-hundred day simple moving average is $54.45. The firm has a market capitalization of $7.39 billion, a price-to-earnings ratio of 19.24, a PEG ratio of 0.44 and a beta of 1.25. Halozyme Therapeutics, Inc. has a 12-month low of $34.36 and a 12-month high of $65.53. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the sale, the director now owns 38,611 shares of the company’s stock, valued at approximately $2,173,799.30. The trade was a 11.46 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 2.40% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts have commented on HALO shares. Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Piper Sandler lifted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. JMP Securities increased their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. Wells Fargo & Company dropped their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $70.00 price target on shares of Halozyme Therapeutics in a report on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $60.89.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.